Dear readers,
We are glad to announce of our new website, There you will continue to have access to the full content of the Sharecast newswire, alongside an improved and expanded suite of market data and research tools for both the UK and the main international markets. As a first step in the transition to the new site, over coming days and weeks the news and data pages on will redirect you towards the new website which we earnestly hope you will find even more useful than the current service. Should anyone like to comment or provide constructive criticism on the new layout or what features they would like to see added or deleted, do please send us an e-mail to Lastly, of course, we wish to express our heartfelt gratitude for your support and encouragement over the years as we continued to grow and expand the service.
Very best,


Glaxo offloads non-core assets in US and Canada

Company News

Glaxo offloads non-core assets in US and Canada

Tue, 20 December 2011
Article viewed 12 times
Glaxo offloads non-core assets in US and Canada
GlaxoSmithKline Quote more

Price: 1,536.00

Chg: 2.50

Chg %: 0.16%

Date: 17:04

Pharmaceuticals giant GlaxoSmithKline, which announced back in February its intention to get rid of its Consumer Healthcare OTC brands, has now reached an agreement with Prestige Brands Holdings to sell these non-core US and Canadian brands for £426m cash.

The brands include BC, Goody's, Beano, Ecotrin, Fiber Choice and Tagamet and generated sales of £134m in 2010 and £98m in the first nine months of this year, the group said. The net profit from their disposal (including transaction costs) will be around £240m pre-tax.

Glaxo said that the net cash proceeds from this transaction, £242m, will be returned to shareholders from next year.

"The disposal of our non-core consumer brands is about realising attractive value for shareholders as well as simplifying our ongoing Consumer business and allowing it to focus on its priority brands and markets," said Chief Financial Officer Simon Dingemans.

Meanwhile, the process of divesting the remaining brands continues but the group assured that any net proceeds from these future sales will be returned to shareholders.

Shares are trading 1.76% lower at 1,424.5p, broadly in line with the pharmaceuticals and biotechnology sector.